886499-74-7

Basic information

• Product Name: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID
• Synonyms: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID;3-[4-(Trifluoromethoxy)phenyl]propanoic acid;4-(Trifluoromethoxy)hydrocinnamic acid, 3-[4-Trifluoromethoxy)phenyl]propionic acid;4-(Trifluoromethoxy)hydrocinnemic acid;4-(TRIFLUOROMETHOXY)HYDROCINNAMIC ACID
• CAS NO: 886499-74-7
• Molecular Formula: C₁₀H₉F₃O₃
• Molecular Weight: 234.17
• Product Categories: Aromatic Propionic Acids
• Mol File: 886499-74-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID(886499-74-7)
• EPA Substance Registry System: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID(886499-74-7)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• WGK Germany: 3
• Hazardous Substances Data: 886499-74-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Trifluoromethoxyphenyl)propionic acid is used as an analgesic and anti-inflammatory agent for the treatment of conditions such as arthritis, menstrual cramps, and other types of chronic pain. Its ability to reduce inflammation and alleviate pain makes it a common choice for managing these conditions.
As a therapeutic intervention, it is typically administered orally and is available in various forms, including tablets and capsules, ensuring patient compliance and ease of use.
However, it is important to note that 2-(4-Trifluoromethoxyphenyl)propionic acid can cause side effects such as stomach irritation, heartburn, and gastrointestinal bleeding. Additionally, its use at high doses or over extended periods may increase the risk of more severe health issues, including heart attack and stroke. Therefore, careful consideration and medical supervision are necessary when prescribing and using this NSAID for treatment.

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 659-28-9 p-trifluoromethoxybenzaldehyde 

Downstream Products

• 1026038-41-4 N-Boc-4-(trifluoromethoxy)phenylethylamine 
• 1412452-70-0 2-(ethylamino)-6-(3-(4-(trifluoromethoxy)phenyl)propanoyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-4-carboxamide 
• 1412452-76-6 C₂₀H₂₁F₃N₄O₄ 
• 1412452-77-7 C₂₁H₂₁F₃N₄O₃ 
• 1000519-40-3 3-(4-trifluoromethoxyphenyl)propan-1-ol 
• 1613696-23-3 5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-2-{2-[4-(trifluoromethoxy)phenyl]ethyl}-1H-benzimidazole 
• 1026522-08-6 5-[2-(5-chloro-2-methoxybenzamido)ethyl]-2-(trifluoromethoxy)benzenesulfonamide 
• 1027243-82-8 5-chloro-2-methoxy-N-(2-(4-trifluoromethoxyphenyl)ethyl)benzamide 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.

Cardioselective KATP channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas

Sulfonylthioureas exhibiting cardioselective blockade of ATP-sensitive potassium channels (KATP channels) were discovered by stepwise structural variations of the antidiabetic sulfonylurea glibenclamide. As screening assays, reversal of rilmaka